219* Monitoring cystic fibrosis patient's adherence to nebulized antibiotics with the i-neb adaptive aerosol delivery (AAD) system  by Gartner, S. et al.
S56 7. Pulmonology
219* Monitoring cystic ﬁbrosis patient’s adherence to nebulised
antibiotics with the i-neb adaptive aerosol delivery (AAD) system
S. Gartner1, C. Martin1, A. Moreno1, P. Calero2, I. de Mir1, A. Torrent1,
S. Rovira1, M. Benavides1, R. Ocan˜a1. 1Hospital Universitari Vall d’Hebron,
Pediatric Pulmonology and Cystic Fibrosis Center, Barcelona, Spain; 2Praxis
Farmaceutical, Departamento Me´dico, Madrid, Spain
Introduction: The i-neb AAD system is a portable mesh nebulizer that provides
precise dosing, feedback to the patient and ability to log information about device
use and performance.
Objective: to assess the adherence and compliance to prescribed treatment of CF
patients to nebulised antibiotic utilising the AAD device.
Methods: 16 cystic ﬁbrosis patients (10 female, age range 8−18 years, mean:
12.31 years) infected with Pseudomonas aeruginosa (PA) and treated with
aerosolised colistin twice a day using the AAD device were included. Data were
downloaded during a clinic visit 3 months later. None of the patients were aware
that the data were recorded.
Results: Mean overall adherence over the 3 months of treatment (number of
recorded doses/number of prescribed doses ×100) was 89.83% (SD: 26.97%)
with 2 out of 16 patients having an overall adherence below 75%. The mean
percentage of days each patient fully adhered was 78.40% (SD: 17.56%) and the
mean of fully compliance was 84.94% (SD: 28.27%). Mean treatment time was
8.2 minutes. Adherence was better, (but statistically not signiﬁcant, p = 0.4) in the
evening (93.92%, SD: 34.24%) than in the morning (85.24%, SD: 22.39%). Also,
no signiﬁcant correlations were observed between better adherence and age, FEV1,
BMI, chronic PA.
Conclusions: The AAD system recording offers very useful information to examine
patterns of adherence during aerosolised therapy and allows to monitor aspects of
the treatment that can be improved. The high level of adherence observed in our
series contrast with the poor compliance reported in previous studies.
220 Respiratory and nutritional effects of long-term treatment with
azithromycin in patients with cystic ﬁbrosis
S. Fustik1, T. Jakovska-Maretti1, L. Spirevska1. 1University Pediatric Clinic,
Centre for Cystic Fibrosis, Skopje, Macedonia, the Former Yugoslav Republic of
Objectives: Macrolides are known to display immunomodulatory effects that have
been reported to be beneﬁcial in various chronic pulmonary inﬂammatory diseases.
The aim of study was to deﬁne whether long-term use of azithromycin (Az) may
be associated with respiratory and nutritional beneﬁts in patients with cystic ﬁbro-
sis (CF).
Methods: The case-notes of CF patients chronically colonized with Pseudomonas
aeruginosa (PA) who had been prescribed Az for at least two years and patients
who were not compliant with therapy were reviewed. The Az group received either
250mg (weight <40 kg) or 500mg (weight >40 kg) every other day. Data collected
included FVC, FEV1, and BMI. Values were obtained from outpatient visits at the
beginning and at the end of two years period.
Results: 38 CF patients with chronic PA infection, aged 9 to 27 years, were
analyzed, 22 in Az group and 16 in non-Az group. The % predicted FVC
at start and at end of study in Az and non-Az groups were respectively
83.2±12.1· · ·86.8±12.8 and 91.8±12.2· · ·85.7±11.9. The increased of FVC was
signiﬁcant in Az group in contrast with signiﬁcant decrease in non-AZ group. The
% predicted FEV1 at start and at end of study in Az and non-Az groups were
respectively 75.5±14.3· · ·76.1±14.8 and 88.6±13.9· · ·79.8±15.1. The difference
was not signiﬁcant in Az group, but the decrease was signiﬁcant in non-Az group.
There was a trend to a signiﬁcant increased in BMI in Az group from 18.5±2.2
to 19.4±2.2 in contrast with non-Az group, where the difference in BMI was not
signiﬁcant.
Conclusion: Our results show that Az long-term treatment may improve the
respiratory function and nutritional status in CF patients.
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cystic ﬁbrosis
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Objectives: CF is characterized by progressive and irreversible lung damage, which
leads to respiratory failure and to cor pulmonale. We evaluated the rate of subclinical
right ventricular dysfunction (RVD), pulmonary hypertension (PH) and impaired
pulmonary vascular impedance (PVI) in adult CF patients (pts) with mild to severe
lung disease. We investigated the relationship between FEV1, FVC, peripheral
oxygen saturation (SpO2) at rest and during exercise and echocardiographic (EC)
abnormalities.
Methods: From May 2006 to July 2009, 101/190 pts attending Adult CF Unit of
Milan, clinically stable and without evident right or left ventricular dysfunctions
(mean age 34 yrs, range 21−56) were investigated with Doppler echocardiography.
We deﬁned the presence of PH if velocity of tricuspid regurgitation ﬂow (TRV) was
>2.5m/s, RVD if tricuspid annular plane systolic excursion rate (TSE) <15 cm/s
and impaired PVI if pulmonary valve acceleration time (PVaccT) <100ms. We
collected FEV1 (mean 60%, range 19–121) and FVC (mean 75%, range 30–116)
and examined SpO2during EC. Oxygen desaturation during exercise was detected
by 6MWT.
Conclusion: In our study 31/98 of pts had PH, 28/62 subclinical RVD and 11/96
impaired PVI. We found a positive relationship between PVaccT and FEV1, FVC
and SpO2. Multivariate regression analysis showed that SpO2 was the best single
predictor of PVI. TSE was signiﬁcantly correlated with FEV1.
In agreement with literature 45.1% pts had subclinical RVD while the prevalence of
PH was lower. We did not ﬁnd any correlation with spirometric values and SpO2.
SpO2 was a good predictor of PVI in pts with different stages of lung disease.
222 Prognostic value of secondary pulmonary hypertension in adults
with cystic ﬁbrosis on the waiting list for lung transplantation
E. Csiszer1, C. Czibo´k2. 1National Koranyi Institute of TB and Pulmonology,
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Objectives: The need for referral for lung transplantation of cystic ﬁbrosis (CF)
patients in end-stage lung disease is determined by several factors. Some of these
may also have prognostic value for the survival on the waiting list and the transplant
outcome.
Methods: We have investigated retrospectively the relation between the appearance
of secondary pulmonary hypertension and the mortality rate of CF patients on the
waiting list. Pulmonary hypertension was estimated on the basis of ﬂow velocity
in tricuspidal insufﬁciency during echocardiography performed before referring
patients to the waiting list. Between January 2000 and January 2011 30 CF patients
were put on the waiting list for lung transplantation.
Results: In 16 patients (group 1) the pulmonary pressure was not increased
(<35mmHg), while in the remaining 14 cases (group 2) it was elevated
(>35mmHg). One patient in group 1 and ﬁve in group 2 died while on the
waiting list. Additionally, three patients in group 2 required an extensive stay at the
intensive care unit post-transplantation in severe clinical condition with extremely
high pulmonary pressure.
Conclusion: Our ﬁndings suggest that pulmonary pressure, as assessed by echocar-
diography, may be regarded as an important prognostic factor for survival of CF
patients on the waiting list for lung transplantation.
